This database contains 664 studies, archived under the term: "Randomised Controlled Trial"
Click here to filter this large number of results.
Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study
Drumond Marra, Hellen Livia,
Myczkowski, Martin Luiz,
Maia Memória, Cláudia,
Arnaut, Débora,
Leite Ribeiro, Philip,
Sardinha Mansur, Carlos Gustavo,
Lancelote Alberto, Rodrigo,
Boura Bellini, Bianca,
Alves Fernandes da Silva, Adriano,
Tortella, Gabriel,
Ciampi de Andrade, Daniel,
Teixeira, Manoel Jacobsen,
Forlenza, Orestes Vicente,
Marcolin, Marco Antonio
Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique with potential to improve memory. Mild cognitive impairment (MCI), which still lacks a specific therapy, is a clinical syndrome associated with increased risk of dementia. This study aims to assess the effects of high-frequency repetitive TMS (HF rTMS) on everyday memory of the elderly with […]
The PACE study: a randomized clinical trial of cognitive activity strategy training for older people with mild cognitive impairment
Vidovich, Mandy R.,
Lautenschlager, Nicola T.,
Flicker, Leon,
Clare, Linda,
McCaul, Kieran,
Almeida, Osvaldo P.
Objective: The role of cognition-focused interventions in reducing cognitive decline in older people remains uncertain. This study aimed to clarify whether a group cognitive activity (CA) strategy-training program would decrease the 2-year rate of cognitive decline of people with mild cognitive impairment (MCI).; Design: Randomized controlled trial.; Setting: One study site.; Participants: 160 older adults […]
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study
Mild cognitive impairment (MCI) in Parkinson’s disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal […]
Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomised controlled trial
ten Brinke, Lisanne F.,
Bolandzadeh, Niousha,
Nagamatsu, Lindsay S.,
Hsu, Chun Liang,
Davis, Jennifer C.,
Miran-Khan, Karim,
Liu-Ambrose, Teresa
Background: Mild cognitive impairment (MCI) is a well-recognised risk factor for dementia and represents a vital opportunity for intervening. Exercise is a promising strategy for combating cognitive decline by improving brain structure and function. Specifically, aerobic training (AT) improved spatial memory and hippocampal volume in healthy community-dwelling older adults. In older women with probable MCI, […]
A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension
Remington, Ruth,
Lortie, Jevin J.,
Hoffmann, Heather,
Page, Robert,
Morrell, Christopher,
Shea, Thomas B.
Thirty-four individuals with mild cognitive impairment were randomized for 6 months to a nutraceutical formulation (NF: folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) or indistinguishable placebo, followed by a 6-month open-label extension in which all individuals received NF. The NF cohort improved in the Dementia Rating Scale (DRS; effect size >0.7) and maintained baseline […]
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Schmitt, Frederick A.,
Aarsland, Dag,
Brønnick, Kolbjørn S.,
Meng, Xiangyi,
Tekin, Sibel,
Olin, Jason T.
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]
Vitamins B₁₂, B₆, and folic acid for cognition in older men
Ford, A. H.,
Flicker, L.,
Alfonso, H.,
Thomas, J.,
Clarnette, R.,
Martins, R.,
Almeida, O. P.
[Correction Notice: An erratum for this article was reported in Vol 77(8) of Neurology (see record [rid]2011-21984-022[/rid]). In the original article, the daily dose of vitamin B12 used in the trial was reported as 400 μg, but it should have been 500 μg.] Objective: To investigate whether supplementing older men with vitamins B12, B6, and […]